Table 3 Univariate and multivariate analyses about survival outcomes in the patients treated with capecitabine/oxaliplatin
Characteristics | Number of patients (%) | Unadjusted HR (95% CI) | P Value | Adjusted HR (95% CI) | P Value | |
|---|---|---|---|---|---|---|
Total | 6,938 (100.0) | |||||
Age, years | < 30 | 48 (0.7) | 1 | 1 | ||
30–39 | 379 (5.5) | 0.77 (0.45–1.33) | 0.353 | 0.89 (0.52–1.54) | 0.680 | |
40–49 | 1,124 (16.2) | 0.77 (0.46–1.30) | 0.324 | 0.91 (0.54–1.53) | 0.724 | |
50–59 | 2,251 (32.4) | 0.69 (0.41–1.15) | 0.156 | 0.81 (0.49–1.36) | 0.431 | |
60–69 | 2,107 (30.4) | 0.71 (0.43–1.19) | 0.197 | 0.83 (0.50–1.40) | 0.491 | |
70–79 | 960 (13.8) | 0.88 (0.52–1.49) | 0.637 | 0.92 (0.54–1.56) | 0.764 | |
≥ 80 | 69 (1.0) | 1.57 (0.82–3.01) | 0.174 | 1.37 (0.71–2.66) | 0.346 | |
Gender | Male | 4,837 (69.7) | 1 | 1 | ||
Female | 2,101 (30.3) | 1.05 (0.94–1.17) | 0.38 | 1.00 (0.90–1.12) | 0.992 | |
Comorbidities | ||||||
DM | No | 5,526 (79.6) | 1 | 1 | ||
Yes | 1,412 (20.4) | 1.01 (0.90–1.15) | 0.828 | 1.02 (0.89–1.17) | 0.767 | |
Hypertension | No | 4,608 (66.4) | 1 | 1 | ||
Yes | 2,330 (33.6) | 0.94 (0.85–1.05) | 0.271 | 0.92 (0.81–1.04) | 0.183 | |
Dyslipidemia | No | 4,761 (68.6) | 1 | 1 | ||
Yes | 2,177 (31.4) | 0.95 (0.85–1.07) | 0.398 | 0.96 (0.84–1.08) | 0.471 | |
COPD | No | 6,356 (91.6) | 1 | 1 | ||
Yes | 582 (8.4) | 1.06 (0.88–1.27) | 0.535 | 0.97 (0.80–1.16) | 0.702 | |
Chemotherapy cycles | ≥ 8 cycles | 4,161 (59.9) | 1 | 1 | ||
7 < cycles < 8 | 514 (7.4) | 1.63 (1.35–1.96) | < 0.0001 | 1.63 (1.35–1.97) | < 0.0001 | |
6 < cycles ≤ 7 | 531 (7.7) | 2.09 (1.76–2.49) | < 0.0001 | 2.10 (1.76–2.49) | < 0.0001 | |
5 < cycles ≤ 6 | 317 (4.6) | 2.63 (2.11–3.27) | < 0.0001 | 2.61 (2.10–3.26) | < 0.0001 | |
≤ 5 cycles | 1,415 (20.4) | 3.20 (2.84–3.61) | < 0.0001 | 3.16 (2.79–3.57) | < 0.0001 | |